MedTrace Logo

Characterize the Regional Distribution of [11C] ABP688 in Brain by Positron Emission Tomography (PET)

NCT01528241 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2020-12-08

No results posted yet for this study

Summary

This study is designed to characterize the regional distribution of \[11C\] ABP688 in brain by positron emission tomography (PET).

Conditions

Interventions

DRUG

ABP688

Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
55 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2010-05-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01528241 on ClinicalTrials.gov